New drug combo aims to wipe out CLL cells, guided by a simple blood test
NCT ID NCT05677919
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two drugs, pirtobrutinib and venetoclax, for people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. The goal is to see if the combination can make cancer undetectable using a sensitive blood test. The treatment length is guided by that test, aiming to personalize therapy and reduce side effects. About 72 adults will take part in this phase 2 trial.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Can a Three-Drug combo outsmart High-Risk CLL?
- Can a gentler dose of zanubrutinib keep CLL at bay in the very elderly?
- Can a Two-Drug combo wipe out hidden leukemia cells?
- Can a Chemo-Free pill combo outsmart leukemia at first diagnosis?